Abstract
Introduction: Asymptomatic and mildly symptomatic dominantly inherited Alzheimer's disease mutation carriers (DIAD-MC) are ideal candidates for preventative treatment trials aimed at delaying or preventing dementia onset. Brain atrophy is an early feature of DIAD-MC and could help predict risk for dementia during trial enrollment. Methods: We created a dementia risk score by entering standardized gray-matter volumes from 231 DIAD-MC into a logistic regression to classify participants with and without dementia. The score's predictive utility was assessed using Cox models and receiver operating curves on a separate group of 65 DIAD-MC followed longitudinally. Results: Our risk score separated asymptomatic versus demented DIAD-MC with 96.4% (standard error = 0.02) and predicted conversion to dementia at next visit (hazard ratio = 1.32, 95% confidence interval [CI: 1.15, 1.49]) and within 2 years (area under the curve = 90.3%, 95% CI [82.3%–98.2%]) and improved prediction beyond established methods based on familial age of onset. Discussion: Individualized risk scores based on brain atrophy could be useful for establishing enrollment criteria and stratifying DIAD-MC participants for prevention trials.
Original language | English |
---|---|
Article number | e12197 |
Journal | Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring |
Volume | 13 |
Issue number | 1 |
DOIs | |
State | Published - 2021 |
Keywords
- Dominantly Inherited Alzheimer Network
- autosomal dominant Alzheimer's disease
- brain atrophy
- preclinical Alzheimer's disease
Fingerprint
Dive into the research topics of 'Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 13, No. 1, e12197, 2021.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease
AU - Dominantly Inherited Alzheimer Network
AU - Keret, Ophir
AU - Staffaroni, Adam M.
AU - Ringman, John M.
AU - Cobigo, Yann
AU - Goh, Sheng Yang M.
AU - Wolf, Amy
AU - Allen, Isabel Elaine
AU - Salloway, Stephen
AU - Chhatwal, Jasmeer
AU - Brickman, Adam M.
AU - Reyes-Dumeyer, Dolly
AU - Bateman, Randal J.
AU - Benzinger, Tammie L.S.
AU - Morris, John C.
AU - Ances, Beau M.
AU - Joseph-Mathurin, Nelly
AU - Perrin, Richard J.
AU - Gordon, Brian A.
AU - Levin, Johannes
AU - Vöglein, Jonathan
AU - Jucker, Mathias
AU - la Fougère, Christian
AU - Martins, Ralph N.
AU - Sohrabi, Hamid R.
AU - Taddei, Kevin
AU - Villemagne, Victor L.
AU - Schofield, Peter R.
AU - Brooks, William S.
AU - Fulham, Michael
AU - Masters, Colin L.
AU - Ghetti, Bernardino
AU - Saykin, Andrew J.
AU - Jack, Clifford R.
AU - Graff-Radford, Neill R.
AU - Weiner, Michael
AU - Cash, David M.
AU - Allegri, Ricardo F.
AU - Chrem, Patricio
AU - Yi, Su
AU - Miller, Bruce L.
AU - Rabinovici, Gil D.
AU - Rosen, Howard J.
N1 - Funding Information: Dr. Clifford Jack serves on an independent data monitoring board for Roche and has consulted for Eisai, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr. Saykin receives support from Arkley BioTek (joint NIH SBIR grant); Avid Radiopharmaceuticals (in kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board); Eli Lilly (collaborative research grant); and Springer‐Nature Publishing (Editorial Office Support as Editor in Chief, ). Ophir Keret is an Atlantic Fellow for Equity in Brain Health and thanks the Global Brain Health Institute for supporting his work. Johannes Levin reports speaker fees from Bayer Vital and Roche; consulting fees from Axon Neuroscience; author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers; non‐financial support from Abbvie; and compensation for duty as part‐time CMO from MODAG, outside the submitted work. John C. Morris reports support from NIH grants P30 AG066444, P01 AG003991, and P01 AG026276 during the conduct of the study. He serves on the Editorial Boards of and . Su Yi was a paid consultant for Green Valley Pharmaceuticals LLC in 2018. Adam M. Staffaroni provides consultation to Takeda and receives research funding from the NIH, the Larry L. Hillblom Foundation, and the Bluefield Project to Cure FTD. Stephan Salloway reports grants, personal fees, and non‐financial support from Biogen; grants and personal fees from Eisai; grants, personal fees, and non‐financial support from Avid; personal fees and non‐financial support from Novartis; grants, personal fees, and non‐financial support from Lilly; personal fees from Genentech; personal fees and non‐financial support from Roche, outside the submitted work. Michael Weiner receives support for his work from the following funding sources: NIH, DOD, PCORI, California Dept. of Public Health, U. Michigan, Siemens, Biogen, Hillblom Foundation, Alzheimer's Association, The State of California, Johnson & Johnson, Kevin and Connie Shanahan, GE, VUmc, Australian Catholic University (HBI‐BHR), The Stroke Foundation, Fidelity Charitable, and the Veterans Administration. Dr. Weiner has served on advisory boards for Cerecin/Accera, Alzheon, Inc., Nestle/Nestec, PCORI/PPRN, Dolby Family Ventures, National Institute on Aging (NIA), Boston University Alzheimer's Disease and CTE Center, MIRIADE at VUmc for Amsterdam UMC, Cytox, Indiana University, Acumen, Brain Health Registry and ADNI. He serves on the Editorial Boards for Alzheimer's & Dementia, TMRI and MRI. He has provided consulting and/or acted as a speaker/lecturer to Cerecin/Accera, Inc., Alzheimer's Drug Discovery Foundation (ADDF), BioClinica, The Buck Institute for Research on Aging, FUJIFILM‐Toyama Chemical (Japan), Garfield Weston, Baird Equity Capital, University of Southern California (USC), T3D Therapeutics, Cytox, Guidepoint, and Japanese Organization for Medical Device Development, Inc. (JOMDD). He holds stock options with Alzheon, Inc., Alzeca, and Anven. Bruce L. Miller reported serving on the advisory committee for Cambridge National Institute for Health Research Biomedical Research Centre; serving on the board of directors for J Douglas French Alzheimer's Foundation and Safely You; serving as medical advisor and receiving grant support from The Bluefield Project for Frontotemporal Dementia Research; consulting for Rainwater Charitable Foundation, Stanford Alzheimer's Disease Research Center, Buck Institute, Larry L. Hillblom Foundation, University of Texas Center for Brain Health, University of Washington Alzheimer's Disease Research Center, and Harvard University Alzheimer's Disease Research Center; receiving royalties from Guilford Press, Cambridge University Press, Johns Hopkins Press, and Oxford University Press; serving as editor for ; serving as section editor for ; and receiving grants P30 AG062422, P01 AG019724, R01 AG057234, and T32 AG023481 from the NIH. Gil D. Rabinovici receives research support from Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare, Genentech, Life Molecular Imaging. He has received consulting fees from Axon Neurosciences, Eisai, Genentech, GE Healthcare, Miller Medical Communications, Roche. He is an Associate Editor for . Howard J. Rosen reported consulting for Wave Neuroscience outside the submitted work. All other authors have no potential conflicts to disclose. Brain Imaging and Behavior Brain & Life Alzheimer's & Dementia Neurocase Frontiers in Neurology JAMA Neurology Funding Information: This research was supported by the National Institutes of Health, grants P01 AG019724, ‐ P30 AG062422, K24 AG045333, U19 AG063911, U01 AG045390, U54 NS092089, U01AG051218, P50AG016570, P50AG005142, K08AG022228, P30 AG066444; P01 AG03991; P01 AG026276; U19 AG032438, P30 AG010133, R01 AG019771, P30 AG010133, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, and U01 AG068057 and the Alzheimer's Association research fellowship to promote diversity grant AARFD‐20‐681815. Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer Network (DIAN, UF1AG032438) funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), with partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI). This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. We acknowledge the altruism of the participants and their families and contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study. Publisher Copyright: © 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association
PY - 2021
Y1 - 2021
N2 - Introduction: Asymptomatic and mildly symptomatic dominantly inherited Alzheimer's disease mutation carriers (DIAD-MC) are ideal candidates for preventative treatment trials aimed at delaying or preventing dementia onset. Brain atrophy is an early feature of DIAD-MC and could help predict risk for dementia during trial enrollment. Methods: We created a dementia risk score by entering standardized gray-matter volumes from 231 DIAD-MC into a logistic regression to classify participants with and without dementia. The score's predictive utility was assessed using Cox models and receiver operating curves on a separate group of 65 DIAD-MC followed longitudinally. Results: Our risk score separated asymptomatic versus demented DIAD-MC with 96.4% (standard error = 0.02) and predicted conversion to dementia at next visit (hazard ratio = 1.32, 95% confidence interval [CI: 1.15, 1.49]) and within 2 years (area under the curve = 90.3%, 95% CI [82.3%–98.2%]) and improved prediction beyond established methods based on familial age of onset. Discussion: Individualized risk scores based on brain atrophy could be useful for establishing enrollment criteria and stratifying DIAD-MC participants for prevention trials.
AB - Introduction: Asymptomatic and mildly symptomatic dominantly inherited Alzheimer's disease mutation carriers (DIAD-MC) are ideal candidates for preventative treatment trials aimed at delaying or preventing dementia onset. Brain atrophy is an early feature of DIAD-MC and could help predict risk for dementia during trial enrollment. Methods: We created a dementia risk score by entering standardized gray-matter volumes from 231 DIAD-MC into a logistic regression to classify participants with and without dementia. The score's predictive utility was assessed using Cox models and receiver operating curves on a separate group of 65 DIAD-MC followed longitudinally. Results: Our risk score separated asymptomatic versus demented DIAD-MC with 96.4% (standard error = 0.02) and predicted conversion to dementia at next visit (hazard ratio = 1.32, 95% confidence interval [CI: 1.15, 1.49]) and within 2 years (area under the curve = 90.3%, 95% CI [82.3%–98.2%]) and improved prediction beyond established methods based on familial age of onset. Discussion: Individualized risk scores based on brain atrophy could be useful for establishing enrollment criteria and stratifying DIAD-MC participants for prevention trials.
KW - Dominantly Inherited Alzheimer Network
KW - autosomal dominant Alzheimer's disease
KW - brain atrophy
KW - preclinical Alzheimer's disease
UR - http://www.scopus.com/inward/record.url?scp=85133499272&partnerID=8YFLogxK
U2 - 10.1002/dad2.12197
DO - 10.1002/dad2.12197
M3 - Article
C2 - 34258377
AN - SCOPUS:85133499272
SN - 2352-8729
VL - 13
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
M1 - e12197
ER -